Ricardo Costa, MD, MSc

Cancer Focus:
Breast Cancer, Ductal Carcinoma In Situ, Inflammatory Breast Cancer, Invasive Ductal Carcinoma, Triple Negative Breast Cancer

Dr. Costa is a Medical Oncologist at the Department of Breast Oncology at Moffitt Cancer Center in the Clinical Investigator Track since 2017. In 2011, Dr. Costa completed a Master Degree in Clinical Research at University of Pittsburgh and Clinical Fellowship Training at Allegheny General Hospital, Pittsburgh, Pennsylvania. Dr. Costa was an Instructor at the Developmental Therapeutics Program at Northwestern University, Chicago, where he developed early phase clinical trials for the treatment of breast cancer. He has already authored and co-authored over 40 scientific manuscripts. His current research projects are focused on the development of Targeted Agents and Immune Therapies, including new vaccines and antibodies, for the treatment of breast cancer. He is currently a Principal Investigator of clinical trials at Moffitt Cancer Center and treats women with all stages of breast cancer.

Education & Training

Board Certification:

• Internal Medicine - Medical Oncology

Fellowship:

• Drexel of Pittsburgh Allegheny General Hospital - Hematology/Oncology
• Northwestern University Feinberg School of Medicine - Developmental Therapeutics

Residency:

• East Tenessee State University - Internal Medicine

Medical School:

• Federal University of Pernambuco, Brazil - MD

Clinical Trial 20897
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and HR Low Positive Breast Cancer (DecipHER)
Condition: Breast
Intervention: Adriamycin (doxorubicin); DC1 Vaccine (); Neulasta (pegfilgrastim); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Taxol (paclitaxel); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); paclitaxel (); pegfilgrastim ()
Status: Open

Clinical Trial 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()
Status: OPEN (SUSPENDED)

Clinical Trial 23756
A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor
Condition: Breast
Intervention: Abemaciclib (); GDC-4198 (); Giredestrant (); LY2835219 (Abemaciclib)
Status: Open

Clinical Trial 24121
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-023 as a single agent, and in combination with AVZO-021 and/or endocrine therapy in patients with advanced solid tumors
Condition: Breast
Intervention: AVZO-021 (); AVZO-023 (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); fulvestrant ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Soyano Muller AE, Goodridge DN, Mo Q, Whiting J, Khakpour N, Lee MC, Laronga C, Armaghani AJ, Han H, Soliman H, Costa R, Loftus L, Hoover SJ, Kiluk JV, Jameel Z, Czerniecki BJ, Khong HT. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2026 Feb.216(1):11. Pubmedid: 41697438.
• Basta A, Lien K, Ni G, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O'Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Cohort Study of the Effectiveness of Trastuzumab Deruxtecan for Treating Metastatic Progressive HER2-Positive Breast Cancer. Clin Breast Cancer. 2026 Aug.26(8):7-13. Pubmedid: 42418955.
• Baumrucker CC, Harris N, Aiello P, Whiting J, Sun W, Soliman H, Han H, Costa R, Czerniecki BJ, Lee MC. Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. J Surg Oncol. 2026 Aug.134(2):220-225. Pubmedid: 42130226. Pmcid: PMC13427119.
• Dacoregio MI, Rego Castro CED, Mamede I, Rodrigues CG, Thimotheo Batista JP, Michelon I, Ribeiro PZ, Oliveira Junior JR, Bonadio RC, Vilbert M, Barros Costa RL. Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis. Breast. 2026 Aug.88:104821. Pubmedid: 42372581. Pmcid: PMC13330674.
• Soliman H, Aldrich A, Abdo N, Han H, Soyano A, Costa R, Armaghani A, Kiluk J, Khakpour N, Lee MC, Hoover S, Laronga C, Niell B, Mooney B, Weinfurtner RJ, Rosa M, Czerniecki B. A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. NPJ Breast Cancer. 2025 Mar.11(1):29. Pubmedid: 40097486. Pmcid: PMC11914126.
• Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS. Phase II trial of brain MRI surveillance in stage IV breast cancer. Neurooncol. 2025 Jul.27(6):1550-1558. Pubmedid: 39851040. Pmcid: PMC12309701.
• Han HS, Aldrich AL, Garg SK, Weinfurtner RJ, Nguyen JV, Mo Q, Whiting J, Childress J, Soliman H, Costa R, Armaghani A, Soyano A, Kiluk J, Hoover S, Lee MC, Khakpour N, Shenoi N, Jameel Z, Koski GK, Czerniecki BJ. Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Feb.11(2):119-127. Pubmedid: 39636623. Pmcid: PMC11622104.
• Dacoregio MI, Michelon I, Ernesto do Rego Castro C, Cezar Aquino de Moraes F, Rossato de Almeida G, Ravani LV, Vilbert M, Barros Costa RL. Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis. Breast. 2025 Feb.79:103853. Pubmedid: 39616817. Pmcid: PMC11648803.
• Basta A, Lien K, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O Apos Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology-Basel. 2025 Aug.1-10. Pubmedid: 40759100.
• Ahmed KA, Kim Y, Kim S, Wang MH, DeJesus M, Arrington JA, Soyano AE, Armaghani AJ, Costa RLB, Loftus LS, Rosa M, Caudell JJ, Diaz R, Etame AB, Tran ND, Soliman H, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. J Immunother Cancer. 2025 Apr.13(4). Pubmedid: 40295143. Pmcid: PMC12039042.
• Sarfraz H, Bari S, Whiting J, Sur M, Mo Q, Armitage M, Costa RLB. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience. Oncology-Basel. 2024 May.102(5):414-424. Pubmedid: 38011835.
• Bari S, Li J, Kang D, Jameel Z, Czerniecki BJ, Costa RLB. A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. Clin Breast Cancer. 2023 Jun.23(4):378-387. Pubmedid: 36805387.
• Han HS, Vikas P, Costa RLB, Jahan N, Taye A, Stringer-Reasor EM. Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between. Am Soc Clin Oncol Educ Book. 2023 Jun.43:e390464. Pubmedid: 37335956.
• Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Feb.29(2):450-457. Pubmedid: 36759673.
• Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Dec.29(12):3270. Pubmedid: 36932246.
• Gallen C, Dukes CW, Aldrich A, Macaisa L, Mo Q, Cubitt CL, Pilon-Thomas S, Giuliano AR, Czerniecki BJ, Costa RLB. Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. Vaccines (Basel). 2022 Nov.10(11). Pubmedid: 36423026. Pmcid: PMC9696551.
• Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35710296. Pmcid: PMC9204433.
• Ramamoorthi G, Kodumudi K, Gallen C, Zachariah NN, Basu A, Albert G, Beyer A, Snyder C, Wiener D, Costa RLB, Czerniecki BJ. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Semin Cancer Biol. 2022 Jan.78:78-89. Pubmedid: 33626407.
• Bari S, Boulware D, Li J, Loftus L, Soyano Muller A, Jameel Z, Khong H, Czerniecki BJ, Costa RLB. A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Breast Cancer (Dove Med Press). 2022 Aug.14:199-210. Pubmedid: 35967746. Pmcid: PMC9365325.
• Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Adv Radiat Oncol. 2021 Sep.6(6):100798. Pubmedid: 34934864. Pmcid: PMC8655428.
• Barakat E, Bibok A, Rishi A, Ahmed A, Frakes JM, Hoffe SE, Armaghani AJ, Soyano AE, Costa RLB, El-Haddad G, Choi J, Kis B. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Adv Radiat Oncol. 2021 Oct.7(1):100838. Pubmedid: 35071835. Pmcid: PMC8767250.
• Sun J, Zhong X, Ma J, Sun W, Han HS, Soliman HH, Loftus LS, Costa RLB, Armaghani AJ, Soyano-Muller AE, Czerniecki BJ, Lee MC, Kiluk JV, Khakpour N, Hoover SJ, Laronga C, Khong HT. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021 Nov.10(21):7665-7672. Pubmedid: 34590788. Pmcid: PMC8559460.
• Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer. 2021 Mar.7(1):26. Pubmedid: 33707440. Pmcid: PMC7952601.
• Oswald LB, Arredondo B, Kadono M, Martinez-Tyson D, Meade CD, Penedo F, Antoni MH, Soliman H, Costa RLB, Jim HSL. A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers. Cancer Med. 2021 Jul.10(14):4823-4831. Pubmedid: 34165265. Pmcid: PMC8290228.
• Soliman H, Hogue D, Han HS, Mooney B, Lima Barros Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H, Czerniecki BJ. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Feb.27(4):1012-1018. Pubmedid: 33219014.
• Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
• Shields M, Mo Q, Armitage M, Sharpe SC, Costa RLB. A systematic review and meta-analysis of selected toxicity endpoints of alpelisib. Oncotarget. 2020 Oct.11(42):3793-3799. Pubmedid: 33144920. Pmcid: PMC7584237.
• Talamantes S, Xie E, Costa RLB, Chen M, Rademaker A, Santa-Maria CA. Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy. Cancer Med. 2020 Oct.9(19):6954-6960. Pubmedid: 32757467. Pmcid: PMC7541144.
• Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020 Mar.6(1):10. Pubmedid: 33574294.
• Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer. 2020 Mar.6:10. Pubmedid: 32195333. Pmcid: PMC7067811.
• Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. Drug Des Devel Ther. 2019 Jan.13:309-316. Pubmedid: 30679903. Pmcid: PMC6338114.
• Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab. 2019 Dec.104(12):6193-6200. Pubmedid: 31276163.
• Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Front Immunol. 2019 Aug.10:1939. Pubmedid: 31475002. Pmcid: PMC6702967.
• Costa RLB, Gradishar WJ. Do Genomic Assays Provide the Necessary Confidence to De-escalate Adjuvant Therapy?. J Clin Oncol. 2018 Mar.36(8):725-727. Pubmedid: 29373092.
• Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018 Jun.169(3):397-406. Pubmedid: 29417298.
• Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, Carneiro B, Matsangou M, Agulnik M, Kopp P, Giles F. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. Oncotarget. 2018 Jun.9(46):28281-28289. Pubmedid: 29963277. Pmcid: PMC6021337.
• Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018 Jul.98:48-58. Pubmedid: 29870876.
• Rossi G, Mu Z, Rademaker A, Austin L, Strickland KS, Lima Barros Costa R, Nagy R, Zagonel V, Taxter TJ, Behdad A, Wehbe FH, Platanias LC, Gradishar W, Cristofanilli M. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clin Cancer Res. 2018 Feb.24(3):560-568. Pubmedid: 29180605.
• Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018 Apr.9(31):22137-22146. Pubmedid: 29774128. Pmcid: PMC5955140.
• Costa RB, Benson A, Yaghmai V, Costa RLB, Zhou H, Behdad A, Kaplan JB, Sadim M, Talamantes S, Kalyan A. An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Case Rep Oncol Med. 2018 Apr.2018:6314392. Pubmedid: 29808141. Pmcid: PMC5902098.
• Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA. Overcoming immunosuppression in bone metastases. Crit Rev Oncol Hematol. 2017 Sep.117:114-127. Pubmedid: 28600175.
• Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ. Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017 Sep.8(40):67782-67789. Pubmedid: 28978071. Pmcid: PMC5620211.
• Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2017 Oct.165(3):585-592. Pubmedid: 28674764.
• Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ. Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. J Gastrointest Oncol. 2017 Oct.8(5):858-866. Pubmedid: 29184690. Pmcid: PMC5674261.
• Costa RLB, Costa-Filho RB, Rosa M, Czerniecki BJ. Occult Breast Carcinoma Presenting as Scalp Metastasis. Case Rep Oncol. 2017 Nov.10(3):992-997. Pubmedid: 29279704. Pmcid: PMC5731106.
• Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017 May.10(1):101. Pubmedid: 28476164. Pmcid: PMC5420131.
• Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017 Jun.9:207-213. Pubmedid: 28652812. Pmcid: PMC5476791.
• Agulnik M, Costa RL, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017 Jan.28(1):121-127. Pubmedid: 27771610. Pmcid: PMC6246191.
• Agulnik M, Costa RLB, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017 Jan.28(1):121-127. Pubmedid: 31792524.
• Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan.8(5):8910-8920. Pubmedid: 27852042. Pmcid: PMC5352453.
• Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb.8(9):16052-16074. Pubmedid: 28030802. Pmcid: PMC5362545.
• Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget. 2017 Feb.8(7):12417-12432. Pubmedid: 27926493. Pmcid: PMC5355355.
• Costa RB, Costa R, Kaplan J, Cruz MR, Shah H, Matsangou M, Carneiro B. A Rare Case of Glioblastoma Multiforme with Osseous Metastases. Case Rep Oncol Med. 2017 Dec.2017:2938319. Pubmedid: 29201475. Pmcid: PMC5671696.
• Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. Cancer Treat Rev. 2017 Dec.61:107-115. Pubmedid: 29125981.
• Costa RLB, Gradishar WJ. Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups. J Glob Oncol. 2017 Aug.3(4):281-284. Pubmedid: 28831435. Pmcid: PMC5560466.
• Costa RLB, Gradishar WJ. Triple-Negative Breast Cancer: Current Practice and Future Directions. J Oncol Pract. 2017 05.13(5):301-303. Pubmedid: 28489982.
• Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016 Oct.7(40):65364-65373. Pubmedid: 27588476. Pmcid: PMC5323161.
• Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol. 2016 Oct. Pubmedid: 27701069.
• Costa R, Carneiro BA, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ. The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget. 2016 Jul.7(29):46734-46749. Pubmedid: 27102148. Pmcid: PMC5216833.
• Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016 Feb.10:873-884. Pubmedid: 27013865. Pmcid: PMC4778792.
• Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016 Aug.7(34):55924-55938. Pubmedid: 27409839. Pmcid: PMC5342462.
• Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ. Is Personalized Medicine Here?. Oncology (Williston Park). 2016 Apr.30(4):293-303, 307. Pubmedid: 27085327.
• Costa R, Costa R, Costa R, Junior GM, Cartaxo HQ, de Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014 Jun.2014:952624. Pubmedid: 24900933. Pmcid: PMC4037124.
• Costa R, Costa R, Bacchi CE, Almeida Filho P. Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol. 2014 Jan.2013:252159. Pubmedid: 24455330. Pmcid: PMC3877610.
• Costa R, Costa R, Costa R. Follicular lymphoma presenting with leptomeningeal disease. Case Rep Hematol. 2014 Dec.2014:767621. Pubmedid: 25544910. Pmcid: PMC4269308.
• Costa R, Costa RB, Bacchi C, Sarinho F. Adenocarcinoma of the lung presenting with atypical cystic brain lesions. BMJ Case Rep. 2014 Apr.2014. Pubmedid: 24717598. Pmcid: PMC3987522.
• Costa R, Fazal S, Kaplan RB, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013 Mar.32 Suppl 1:S79-S82. Pubmedid: 20556455.
• Silva Junior GB, Libório AB, Vieira AP, Bem AX, Lopes Filho AS, Figueiredo Filho AC, Guedes AL, Souza JH, Costa CM, Costa R, Daher EF. Evaluation of renal function in sickle cell disease patients in Brazil. Braz J Med Biol Res. 2012 Jul.45(7):652-655. Pubmedid: 22584642. Pmcid: PMC3854265.
• Barros Costa RL. Targeted therapy: comprehensive review. Am J Hosp Palliat Care. 2009 Apr.26(2):137-146. Pubmedid: 19229068.
• Costa R, Costa-Filho RB, Talamantes SM, Queiroga F, Campello EC, Cartaxo H, Costa RB. Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review. Case Rep Oncol. 10(2):524-530. Pubmedid: 28690527. Pmcid: PMC5498939.